Astra Zeneca's ambition is to become the world leader in cardiovascular drugs by 2010. The company currently ranks No. 5 in cardiovascular drugs. The company believes that although the current best-selling ACE inhibitor Zestril (lisinopril) is patented from 2001 to 2002, the newly developed super statin drug ZD-4522 and oral thrombin inhibitor H376-95 will help The company achieves this ambitious goal. The company believes that ZD-4522’s sales will surpass Warner Lambert’s HMGCoA reductase inhibitor Lipitor (atorvastatin), which currently has the strongest sales momentum, and H376/95 can replace vitamin K antagonists and low molecular weight heparin.